Johnson & Johnson (JNJ) to Withdraw the LINC Reflux Management System from Markets Outside the U.S.

With significant upside potential, Johnson & Johnson (NYSE:JNJ) secures a spot on our list of the 13 Best Diversified Stocks to Buy According to Hedge Funds.

On September 23, 2025, Johnson & Johnson (NYSE:JNJ) announced that it will withdraw the LINC Reflux Management System from markets outside the U.S. by the end of March 2026 for commercial reasons. The LINC Reflux Management System is a device used to treat chronic gastroesophageal reflux disease. Meanwhile, the flexible ring of magnets placed around the muscles at the base of the esophagus to prevent acid reflux will remain available in the U.S.

Amid this development, Guggenheim raised its price target on Johnson & Johnson (NYSE:JNJ) from $167 to $206. The investment firm cited the company’s strong top-line growth in 2025 despite Stelara’s loss of exclusivity. Furthermore, Guggenheim believes that the company’s recently launched bladder cancer drugs Inlexzo (TAR-200) and TAR-210 can generate over $6 billion in sales at peak.

Johnson & Johnson (NYSE:JNJ) is focused on research and development, manufacturing, and sales of a broad range of healthcare products globally. It operates across pharmaceuticals, medical devices, and consumer health markets. It is one of the Best Diversified Stocks.

While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 15 Stocks That Will Benefit From AI and 12 Best Quantum Computing Stocks to Buy According to Wall Street Analysts.

Disclosure: None.